(Q37857853)

24 August 2017

1 reference

title

The Syk kinase as a therapeutic target in leukemia and lymphoma (English)

1 reference

24 August 2017

1 reference

Dimitar G Efremov

1

0 references

author name string

Luca Laurenti

series ordinal

2

1 reference

PubMed ID

21438742

24 August 2017

language of work or name

English

0 references

publication date

26 March 2011

1 reference

Expert Opinion on Investigational Drugs

24 August 2017

1 reference

24 August 2017

20

1 reference

24 August 2017

5

1 reference

24 August 2017

623-636

1 reference

The tipping points in the initiation of B cell signalling: how small changes make big differences.

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Regulation of B-cell fate by antigen-receptor signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

ITAM-mediated tonic signalling through pre-BCR and BCR complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

The SYK tyrosine kinase: a crucial player in diverse biological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Syk and pTyr'd: Signaling through the B cell antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Structural basis for the inhibition of tyrosine kinase activity of ZAP-70

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Phosphorylation of the activation loop tyrosines is required for sustained Syk signaling and growth factor-independent B-cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

AKT/PKB signaling: navigating downstream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Src family kinases: regulation of their activities, levels and identification of new pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Essential function for the GTPase TC21 in homeostatic antigen receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

PI3 kinase signals BCR-dependent mature B cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Mechanisms of B-cell lymphoma pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Chronic lymphocytic leukemia: revelations from the B-cell receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Syk-dependent mTOR activation in follicular lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Proteomic and genetic approaches identify Syk as an AML target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

The protooncogene MYC can break B cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Augmentation of the antileukemia potency of total-body irradiation (TBI) by a novel P-site inhibitor of spleen tyrosine kinase (SYK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Alemtuzumab therapy in B-cell lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

Primary Cutaneous B-Cell Lymphoma and Borrelia burgdorferi Infection in Patients From the Highlands of Scotland

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.570329

10.1517/13543784.2011.570329

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21438742